Recent Updates
Recently added Catalysts
APLS

Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference

Key Takeaway: WALTHAM, Mass., May 08, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14,

Full Press Release Details

WALTHAM, Mass., May 08, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 8:20 a.m. ET. The conference will be held in a virtual meeting format.
Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat. The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at http://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
Sam Martin / Maghan Meyers
Last updated: May 8, 2020